1. Home
  2. TRS vs DMRA Comparison

TRS vs DMRA Comparison

Compare TRS & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriMas Corporation

TRS

TriMas Corporation

SELL

Current Price

$36.91

Market Cap

1.3B

Sector

Industrials

ML Signal

SELL

Logo Damora Therapeutics Inc. Common Stock

DMRA

Damora Therapeutics Inc. Common Stock

SELL

Current Price

$22.10

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TRS
DMRA
Founded
1986
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
TRS
DMRA
Price
$36.91
$22.10
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$45.00
★ $46.78
AVG Volume (30 Days)
404.4K
★ 478.7K
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 0.44%
N/A
EPS Growth
N/A
★ 121.48
EPS
★ 22.64
N/A
Revenue
★ $645,720,000.00
N/A
Revenue This Year
$5.16
N/A
Revenue Next Year
$1.55
N/A
P/E Ratio
$1.61
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.67
$16.50
52 Week High
$45.43
$34.89

Technical Indicators

Market Signals
Indicator
TRS
DMRA
Relative Strength Index (RSI) 38.45 50.70
Support Level $35.40 $18.03
Resistance Level $40.10 $27.40
Average True Range (ATR) 1.37 1.83
MACD -0.25 0.05
Stochastic Oscillator 18.40 36.57

Price Performance

Historical Comparison
TRS
DMRA

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: